Current Report Filing (8-k)
March 02 2023 - 7:31AM
Edgar (US Regulatory)
0001651407
false
0001651407
2023-02-27
2023-02-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 27, 2023
Checkpoint Therapeutics, Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-38128 |
|
47-2568632 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer Identification Number) |
95 Sawyer Road, Suite 110, Waltham, MA 02453
(Address of principal executive offices)
(781) 652-4500
Registrant’s telephone number, including
area code
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, $0.0001 par value per share |
|
CKPT |
|
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company x
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
On March 2, 2023, Checkpoint
Therapeutics, Inc. (the “Company”) issued a press release announcing the U.S. Food and Drug Administration’s acceptance
for filing of a Biologics License Application for cosibelimab, its investigational anti-PD-L1 antibody, as a treatment for patients with
metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery
or radiation.
A copy of the Company’s press release is furnished herewith as
Exhibit 99.1.
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CHECKPOINT THERAPEUTICS, INC. |
|
|
|
Date: March 2, 2023 |
By: |
/s/ James F. Oliviero |
|
Name: |
James F. Oliviero |
|
Title: |
President and Chief Executive Officer |
Checkpoint Therapeutics (NASDAQ:CKPT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Checkpoint Therapeutics (NASDAQ:CKPT)
Historical Stock Chart
From Jul 2023 to Jul 2024